Home › Cancer (all types) › NCT06926816

Universal Genetic Testing for Cancer Risk Reduction

Who can join

Ages 25 to 39 · Women · Healthy volunteers welcome

Inclusion Criteria:

1. Female patients between ages of 25-39 years at the time of visit
2. Receive gynecologic care at an affiliated NYU Langone Health (NYULH) site listed in this protocol.

Exclusion Criteria:

1. Personal history of ovarian, fallopian tube, primary peritoneal, or uterine cancers
2. Previously undergone germline testing for ovarian cancer risk variants (prior commercial saliva-based kits, such as 23andMe, are acceptable)
3. History of bilateral salpingo-oophorectomy
4. Visit related to pregnancy or immediately postpartum (within 2 weeks)

About the study

The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to see specialized providers or needing to meet specific criteria. The primary aim to assess the proportion of patients who undergo genetic testing, and the proportion of patients with pathogenic variants.

What is being tested

• Natera® Empower™ hereditary cancer panel test (genetic)
• Specialist Referral (other)

Sponsor: NYU Langone Health · Participants: 600 · Started: Mar 4, 2025

Contact the study team

• Bhavana Pothuri, MD, MS · Phone: 212-731-6455
• Sarah Lee · Phone: 646-501-7876

Official record on ClinicalTrials.gov — NCT06926816

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.